Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery

Fidia Farmaceutici s.p.a.50 enrolled

Overview

This is a Prospective, single-center, randomized, controlled, paired-eye, single-masked clinical investigation to compare the efficacy and safety of FIDIAL PLUS (bacterial derived 1.8% sodium hyaluronate OVD) and IAL®-F (comparable animal derived 1.8% sodium hyaluronate OVD) while used during phacoemulsification cataract surgery.

Viscoelastics, also referred to as OVDs (ophthalmic viscosurgical devices), are viscous substances that are routinely used in cataract surgery. The most basic benefit of OVD use in ophthalmic surgery is maintaining the anterior chamber during surgical maneuvers. One of the main aspects in OVD use remains the protection of intraocular structures and in particular of corneal endothelium cells (CECs) during cataract surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Cataract

Interventions

FIDIAL PLUSDEVICE

1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).

IAL®-FDEVICE

Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject able to comprehend the full nature and the purpose of the study; 2. Subjects able to cooperate with the Investigator and to comply with the requirements of the entire study; 3. Subject provided written informed consent to participate in the study obtained according to Good Clinical Practice (GCP); 4. Females of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status - or not postmenopausal) must have a negative urine pregnancy test result at Screening and surgery days and must use an appropriate method of contraception for at least 30 days before inclusion in the study and during the whole study period, according to the definition in ICH M3 Guideline. The following criteria apply to both eyes: 1. Nuclear cataract with visual acuity between 20/200 (logmar 1.0) and 20/32 (logmar 0.2); 2. Intraocular pressure (IOP) between 14 and 21 mmHg (Goldmann tonometer); 3. Previous refraction between -5 and +3 diopters in spherical equivalent; 4. Corneas perfectly transparent without leukoma or other corneal pathology. Exclusion Criteria: 1. Any acute, chronic or uncontrolled disease as severe heart failure, recent cardiovascular event, respiratory failure, severe hepatic or renal disease, poorly controlled diabetes mellitus, active severe autoimmune disease, active malignancy etc. that in the opinion of the Investigator, would increase the risk of operation or affect the outcome of the study; 2. Epilepsy and any other condition that would prevent cooperation during surgery, including head tremor, deafness, neck or back problems, restless legs syndrome, claustrophobia etc.; 3. Have a history of allergic/hypersensitivity reaction to sodium hyaluronate (NaHA); 4. Participation in another clinical trial within the past 30 days; The following criteria apply both eyes: 1. Corneal endothelium cell density less than 1800 cells/mm square; 2. Pseudoexfoliation syndrome (PEX) or suspected zonular compromise of any origin; 3. Corneal angle narrow or/and glaucoma; 4. Anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation etc.); 5. Any corneal irregularity or leukoma (as assessed by slit lamp and specular microscope pachymetry); 6. Complicated cataracts; 7. Subjects requiring implantation of toric lenses; 8. Proliferative retinopathy, macular degeneration or oedema of any origin. Other ocular pathology that may compromise vision despite successful cataract surgery; 9. Signs of ocular or systemic infection and/or inflammation; 10. Previous intraocular surgery, refractive surgery or severe ocular trauma.

Locations (1)

Azienda Ospedaliera Universitaria Integrata di Verona

Verona, Italy

Outcomes

Primary Outcomes

Change of corneal endothelium cell density after phacoemulsification cataract surgery with use of two different OVD (Ophthalmic Viscosurgical Devices)

This outcome will be calculated as percentage of corneal endothelial cells loss at day 28 (T3/T6) when compared with baseline (T0). This will be assessed as a paired t-test comparing the mean percentage change of FIDIAL PLUS against the mean percentage change from baseline of IAL®-F at Day 28. Corneal endothelial cell density will be measured by non-contact specular microscopy.

Time frame: 28 days per eye

Secondary Outcomes

Incidence of a significant (≥30 mmHg) rise in IOP (Intraocular pressure) during study duration

This will be assessed using McNemar's test to assess the difference in proportion of eyes with a significant rise in IOP during the investigation to the proportion of eyes without a significant rise in IOP during the investigation. IOP will be measured with Goldmann tonometer and expressed in millimeters of mercury (mmHg).

Time frame: 28 days per eye

Incidence of ocular Treatment Emergent Adverse Events (TEAEs)

TEAEs are AE reported from the time of the first application of the medical device (MD). TEAEs will be recorded and reported on the case report form (CRF). They will be tabulated by System Organ Class (SOC) and Preferred Term (PT) after medical coding using the Medical Dictionary for Regulatory Activities (MedDRA).

Time frame: up to 28 days

Incidence of serious ocular Treatment Emergent Adverse Events

Serious TEAEs are AE reported from the time of the first application of the medical device (MD) that led to: death; to a serious deterioration in health that resulted in a life-threatening illness or injury, or resulted in a permanent impairment of a body structure or a body function, or required in-patient hospitalization or prolongation of existing hospitalization, or resulted in medical or surgical intervention to prevent life threatening illness or injury or permanent impairment to a body structure or a body function; led to foetal distress, foetal death or a congenital abnormality or birth defect.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.